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A higher body mass index (BMI) is a predictor of better
survival in hemodialysis patients, although the relative
importance of body fat and lean mass has not been
examined in the dialysis population. We performed an
observational cohort study in 808 patients with end-stage
renal disease on maintenance hemodialysis. At baseline, fat
mass was measured by dual-energy X-ray absorptiometry
and expressed as fat mass index (FMI; kg/m2). Lean mass
index (LMI) was defined as BMI minus FMI. During the mean
follow-up period of 53 months, 147 deaths, including 62
cardiovascular (CV) and 85 non-CV fatal events, were
recorded. In univariate analysis, LMI was not significantly
associated with CV or non-CV death, whereas a higher FMI
was predictive of lower risk for non-CV death. Analyses with
multivariate Cox models, which took other confounding
variables as covariates, indicated the independent
associations between a higher LMI and a lower risk of CV
death, as well as between a higher FMI and a lower risk of
non-CV death. These results indicate that increased fat mass
and lean mass were both conditions associated with better
outcomes in the dialysis population.
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Mortality rate is very high in patients with end-stage renal
disease (or stage 5 chronic kidney disease) treated with
hemodialysis, and the relative risk of death from cardiovas-
cular (CV) events is 10–30 times higher in such patients as
compared with the general population.1 The causes for the
elevated death rate include multiple factors such as the
presence of hypertension,2 hypotension,2,3 dyslipidemia,4,5
abnormalities in bone and mineral homeostasis,6,7 and
impaired metabolism of carbohydrate and insulin resistance.8
In addition, atherosclerosis often coexists with inflammation
and malnutrition in hemodialysis patients,9–11 and a low
body mass index (BMI) and a low serum albumin level, the
markers of malnutrition, are both predictors of poor survival
in hemodialysis patients.12,13
Patients with advanced stages of chronic kidney disease
suffer from protein-energy malnutrition.14 Protein-energy
malnutrition can be defined as a state where net nutrient
intake is lower than nutrient requirements, ultimately leading
to various metabolic abnormalities, decreased tissue function,
and loss of body mass.15 Body mass consists of fat mass and
fat-free mass (lean mass). Lean mass can serve as an index of
muscle mass and somatic protein storage, whereas fat
mass more directly reflects energy storage. Therefore,
reduction of BMI may indicate deteriorations in either of
these two components of protein-energy malnutrition.
Combe et al.16 reported no significant association between
mortality risk and lean mass indirectly estimated from
creatinine generation. In contrast, Arora et al.17 found that
total body protein estimated as a nitrogen index by in vivo
neutron activation analysis was predictive of death in a study
of 76 hemodialysis patients. So far, however, there is no study
in the literature that examined the relative importance of fat
mass and lean mass in determining outcomes of patients on
hemodialysis.
In the present study, by using dual-energy X-ray
absorptiometry (DEXA) that provides reliable information
on body composition, we evaluated the differential contri-
butions of fat mass and lean mass to outcomes in an
observational cohort of hemodialysis patients.
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RESULTS
Body composition at baseline
BMI was positively correlated with fat mass index (FMI)
(r¼ 0.699, Po0.0001) and lean mass index (LMI) (r¼ 0.594,
Po0.0001), respectively, in the total subjects (Figure 1). The
correlations of BMI with FMI and LMI were again significant
when men (r¼ 0.763 and 0.708, Po0.0001 for both) and
women (r¼ 0.863 and 0.588, Po0.0001 for both) were
separately analyzed. However, a weak but statistically
significant inverse correlation was found between FMI and
LMI in the total subjects (r¼0.160, Po0.0001). This may
be due to a lower FMI (3.9271.88 vs 5.7472.53, Po0.001)
and a higher LMI (17.0971.72 vs 14.5671.58, Po0.001) in
men than in women. In fact, the inverse correlation was not
confirmed when men (r¼ 0.084, P¼ 0.063) and women
(r¼ 0.100, P¼ 0.078) were separately analyzed (for baseline
characteristics of the subjects, see Table 1).
Correlations of body composition with other variables at
baseline
Table 2 shows the correlations of BMI, FMI, and LMI with
other clinical data at baseline. BMI was correlated with
dialysis duration (negatively) and serum creatinine (posi-
tively). FMI was correlated with systolic blood pressure (BP)
(negatively), diastolic BP (negatively), and total cholesterol
(positively). LMI was correlated with dialysis duration
(negatively), systolic BP (positively), diastolic BP (positively),
serum creatinine (positively), serum albumin (positively),
and total cholesterol (negatively). As some of these corre-
lations had only very low r-values, their clinical significance is
unknown.
Outcome of the subjects
During the mean follow-up period of 54 months, 147
patients died from CV (N¼ 62) and non-CV (N¼ 90) fatal
events. CV deaths included deaths from ischemic heart
disease (N¼ 15), cerebrovascular disease (N¼ 11), congestive
heart failure (N¼ 27), and sudden deaths (N¼ 9). Non-CV
causes consisted of infectious disease (N¼ 24), cancer
(N¼ 20), hepatic cirrhosis (N¼ 7), and others (N¼ 34).
The mortality rate of this cohort (4% per year) was lower
than that of the Japanese (6.4%), the European (15.6%), and
the US (21.7%) dialysis patients in the dialysis outcomes and
practice patterns study.18
Kaplan–Meier analyses
Kaplan–Meier analyses were performed to examine the
univariate associations between body composition and
outcomes of the cohort. Figure 2 gives the relationship
between the BMI tertiles and the outcomes. Patients in the
lowest tertile of BMI showed the highest risk of death from
all causes (P¼ 0.091). This was due to the elevated risk for
non-CV disease (CVD) death (P¼ 0.008) in the lowest BMI
tertile.
Figure 3 gives the Kaplan–Meier curves based on the FMI
tertiles. Patients in the highest FMI tertile had the lowest risk
for all-cause mortality, although it was not statistically
significant (P¼ 0.134). The patients in the highest FMI tertile
showed a significantly reduced risk for non-CVD mortality
(P¼ 0.004).
Similar analyses were performed for LMI (Figure 4),
although no significant univariate association was found
between the LMI tertiles and the risk of death from all-cause,
CVD, or non-CVD events.
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Figure 1 | Correlation between BMI, FMI, and LMI in the total subjects at baseline.
Table 1 | Baseline characteristics of the hemodialysis cohort
Total number 808
Gender (female:male) 313:495
Diabetes (diabetes:non-diabetes) 161:647
Age (years) 55.1711.4
Dialysis duration (months) 70.1766.2
Systolic BP (mm Hg) 154721
Diastolic BP (mm Hg) 81710
Creatinine (mg/dl) 11.872.6
C-reactive protein (mg/dl) 0.3 (0.05–10.5)
Albumin (g/dl) 3.7870.36
Total cholesterol (mg/dl) 164738
Albumin-corrected calciumphosphate (mg2/dl2) 54.7713.4
Hematocrit (%) 28.774.2
BMI (kg/m2) 20.772.9
FMI (kg/m2) 4.672.3
LMI (kg/m2) 16.172.1
The data are summarized as number, ratio, or mean7s.d. As C-reactive protein had
a skewed distribution, the median (range) is given.
BMI, body mass index; BP, blood pressure; FMI, fat mass index; LMI, lean mass index.
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Univariate analysis with Cox proportional hazards models
As the relationship between body composition and mortality
rate is sometimes U-shaped, we checked for such a possibility
with a Cox model, including BMI and BMI-squared as
covariates. BMI-squared was not significant, indicating no
significant U-shaped relationship. In similar analyses with the
pair of FMI and FMI-squared as well as LMI and LMI-
squared, we again failed to find significant U-shaped
relationship between the body composition indices and
outcomes. Therefore, we did not include BMI-squared, FMI-
squared, or LMI-squared terms for further analyses.
Table 3 summarizes the univariate associations between
the risk of death (all-cause, CVD, or non-CVD) and possible
predictors, including BMI, FMI, and LMI. A higher BMI was
predictive of a reduced risk for all-cause and non-CVD
deaths. A higher FMI predicted a significantly reduced risk of
non-CVD death, whereas it predicted an increased risk of
CVD mortality at a borderline significance. LMI did not
significantly predict all-cause, CVD, or non-CVD death.
A higher age, the presence of diabetes mellitus, and a
higher systolic BP were the significant predictors of an
increased risk for all-cause mortality. This was also true for
death from CVD and non-CVD. An elevated C-reactive
protein (CRP) was a predictor of increased risk for all-cause
mortality. Female gender, a higher serum albumin, and a
higher creatinine were predictors for a reduced risk of all-
Table 2 | Correlation between body composition and other clinical variables
BMI FMI LMI
r P r P r P
Age 0.020 0.58 0.048 0.71 0.081 0.02
HD duration 0.146 o0.01 0.057 0.10 0.137 o0.01
Systolic BP 0.028 0.44 0.146 o0.01 0.201 o0.01
Diastolic BP 0.049 0.17 0.098 o0.01 0.177 o0.01
Creatinine 0.236 o0.01 0.047 0.18 0.379 o0.01
Albumin 0.046 0.20 0.011 0.77 0.074 0.04
Cholesterol 0.054 0.12 0.216 o0.01 0.167 o0.01
Calciumphosphate 0.030 0.40 0.017 0.63 0.022 0.54
Hematocrit 0.018 0.61 0.028 0.43 0.007 0.85
Log CRP 0.010 0.78 0.001 0.98 0.012 0.73
The table gives simple correlation coefficients (r-values) with level of significance (P-values).
Calcium phosphate product was adjusted by serum albumin.
BMI, body mass index; BP, blood pressure; CRP, C-reactive protein; FMI, fat mass index; HD, hemodialysis; LMI, lean mass index.
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Figure 2 | Survival curves of hemodialysis patients based on
tertiles of BMI. The total cohort was divided into tertiles based on
BMI, and survival curves were compared by the Kaplan–Meier analysis
and log-rank test.
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Figure 3 | Survival curves of hemodialysis patients based on
tertiles of FMI. The total cohort was divided into tertiles based on
FMI, and survival curves were compared by the Kaplan–Meier analysis
and log-rank test.
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Figure 4 | Survival curves of hemodialysis patients based on
tertiles of LMI. The total cohort was divided into tertiles based on
LMI, and survival curves were compared by the Kaplan–Meier analysis
and log-rank test.
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cause and non-CVD deaths. A high total cholesterol level
predicted an increased risk of CVD mortality at a borderline
significance. An elevated calcium-phosphate product was a
predictor of a reduced risk of non-CVD death.
Multivariate analysis with Cox proportional hazards models
As the body composition indices were correlated with other
clinical variables that were univariate predictors of outcome,
we performed multivariate Cox analyses. In addition to FMI
and LMI, the other 10 covariates in Table 3 were entered to
the models, and independent associations with the outcomes
were evaluated by a stepwise procedure. Table 4 summarizes
the final results. The significant independent predictors for
all-cause mortality were a higher age, the presence of diabetes
mellitus, a reduced albumin, a low creatinine, and a reduced
FMI. The significant independent predictors for CVD
mortality were a higher age, the presence of diabetes mellitus,
and a reduced LMI. The significant independent predictors
for non-CVD death were a higher age, the presence of
diabetes mellitus, reduced serum levels of albumin, total
cholesterol and creatinine, and a low FMI.
Similar analyses were performed using the same multi-
variate models in which FMI and LMI were replaced with fat
mass (kg), lean mass (kg), and height (m). We found a
significant and independent association of fat mass with non-
CVD mortality, but no significant association of lean mass
with outcomes, suggesting that the effect of body composi-
tion on mortality is more sensitively detected by using FMI
and LMI.
As lean body mass is generally reduced in diabetic dialysis
patients, but falsely increased in those with polycystic kidney
disease, we confirmed the impacts of body composition in a
subgroup of the cohort, excluding diabetic and polycystic
kidney disease patients using the same multivariate Cox
Table 3 | Univariate predictors of death in the hemodialysis cohort
All-cause CVD Non-CVD
Age (per year) 1.076*** (1.061–1.092) 1.068*** (1.043–1.094) 1.081*** (1.062–1.101)
HD duration (per month) 0.999 (0.997–1.002) 0.999 (0.995–1.003) 1.000 (0.997–1.003)
Gender (female vs male) 0.718* (0.515–0.999) 0.939 (0.555–1.590) 0.607* (0.395–0.932)
Diabetes mellitus (vs non-diabtes) 3.792*** (2.713–5.300) 4.286*** (2.503–7.339) 3.513*** (2.286–5.399)
Systolic BP (per 1 mm Hg) 1.015*** (1.007–1.023) 1.015* (1.002–1.028) 1.015** (1.004–1.025)
Log CRP (per 1 log-unit) 1.484* (1.000–2.203) 1.448 (0.768–2.729) 1.508 (0.911–2.497)
Albumin (per 1 g/dl) 0.347*** (0.221–0.547) 0.607 (0.285–1.297) 0.250*** (0.142–0.441)
Total cholesterol (per 1 mg/dl) 1.000 (0.996–1.004) 1.006# (1.000–1.012) 0.996 (0.991–1.002)
Calciumphosphate (per 1 mg2/dl2) 0.991 (0.979–1.003) 1.004 (0.985–1.024) 0.983* (0.967–0.999)
Creatinine (per 1 mg/dl) 0.823*** (0.776–0.873) 0.875** (0.793–0.964) 0.793*** (0.736–0.855)
BMI (per 1 kg/m2) 0.933* (0.881–0.989) 1.012 (0.926–1.106) 0.993*** (0.821–0.955)
FMI (per 1 kg/m2) 0.937# (0.872–1.007) 1.089# (0.985–1.203) 0.833*** (0.753–0.922)
LMI (per 1 kg/m2) 0.953 (0.883–1.029) 0.906 (0.798–1.029) 0.982 (0.892–1.081)
The table gives hazard ratios and 95% confidence intervals by univariate Cox proportional hazards model.
Calcium phosphate product was adjusted by serum albumin.
CRP (mg/dl) was log-transformed and entered into the model because of its skewed distribution.
BMI, body mass index; BP, blood pressure; CRP, C-reactive protein; CVD, cardiovascular disease; FMI, fat mass index; HD, hemodialysis; LMI, lean mass index.
#P=0.05–0.09, *Po0.05, **Po0.01, ***Po0.001.
Table 4 | Multivariate predictors of death in the hemodialysis cohort
All-cause CVD Non-CVD
Age (per year) 1.066*** (1.057–1.076) 1.060*** (1.045–1.075) 1.075*** (1.063–1.087)
HD duration (per month) — — —
Gender (female vs male) — — —
Diabetes mellitus (vs non-diabtes) 2.727*** (2.270–3.274) 3.853*** (2.858–5.197) 2.459*** (1.943–3.114)
Systolic BP (per 1 mm Hg) — — —
Log CRP (per 1 log-unit) — — —
Albumin (per 1 g/dl) 0.503** (0.391–0.648) — 0.399** (0.291–0.546)
Total cholesterol (per 1 mg/dl) — — 0.994* (0.991–0.997)
Calciumphosphate (per 1 mg2/dl2) — — —
Creatinine (per 1 mg/dl) 0.931* (0.897–0.966) — 0.880** (0.840–0.896)
FMI (per 1 kg/m2) 0.926* (0.891–0.962) — 0.850** (0.806–0.896)
LMI (per 1 kg/m2) — 0.874* (0.814–0.938) —
Global model significance Po0.0001 Po0.0001 Po0.0001
The table gives hazard ratios by stepwise multivariate Cox analyses.
Calcium phosphate product was adjusted by serum albumin.
BP, blood pressure; CRP, C-reactive protein; CVD, cardiovascular disease; FMI, fat mass index; HD, hemodialysis; LMI, lean mass index.
*Po0.05, **Po0.01, ***Po0.001.
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models shown in Table 4. The protective effect of FMI against
non-CVD death was significant, whereas the effect of LMI on
CVD death was not significant in this subpopulation.
DISCUSSION
Protein-energy malnutrition is common among patients with
advanced stages of chronic kidney disease.14 A higher BMI is
an independent predictor of better survival in hemodialysis
patients,12,13 although the relative importance of fat mass and
lean mass remains unknown. In the present observational
cohort study, we examined the outcome of hemodialysis
patients in relation to their body composition by using
DEXA, and found that a higher FMI was associated with a
lower mortality rate, particularly that of non-CVD causes.
Also, a higher LMI was an independent predictor for a lower
risk of CVD death. This is the first study showing that both
fat mass and lean mass are the important predictors of
survival in hemodialysis patients.
There is only one study19 in the literature that examined
the relationship between DEXA-based body composition and
the outcome of hemodialysis patients. Kato et al.19 showed
that a lower ratio of limb/trunk lean mass by DEXA was a
significant predictor of a higher risk of all-cause mortality in
men, and that a lower percentage of fat content in the trunk
was a significant predictor of death in women. Although they
suggested the importance of regional body composition, their
study did not answer which is more predictive of outcome of
hemodialysis patients, total body fat mass, or lean mass. We
tried to answer this question, and found that a higher FMI
was an independent predictor of a lower risk of all-cause and
non-CVD death, and that a higher LMI was an independent
predictor of a lower risk of CVD mortality.
The present results indicate that body fat has a protective
role against death in the hemodialysis patients. This is in
sharp contrast to the fact that increased body fat is an
established risk factor of CVD and other health problems in
the general population. Although we have no clear explana-
tion for this apparent discrepancy, we speculate that adipose
tissue has both potentially harmful and beneficial functions
for health and survival, and that the beneficial functions may
exceed the harmful effects in hemodialysis patients. The
favorable actions of adipose tissue are presumably based on
energy storage. When a patient is ill, due to infection, for
example, he/she requires more energy to survive in the ill
condition. Because fat is a more efficient source of energy
than non-fat nutrients, it is conceivable that ill patients with
greater fat mass have a better chance to survive. Indeed, a
similar epidemiology between a higher BMI and a better
survival is also known in some populations other than
hemodialysis patients, such as the elderly individuals,20–23
patients with congestive heart failure,24 older women with
cancer,25 and patients with lung cancer after surgery,26
although these studies did not directly measure body fat. We
speculate that the beneficial effects of adipose tissue on
survival are more apparent after the subjects become ill than
before the subjects get the illness.
Another explanation for the reverse epidemiology in
hemodialysis patients is the possible changes in adipocyte
functions in renal failure. As adipose tissue secretes both
atherogenic and anti-atherogenic factors called adipocyto-
kines, alterations in adipocytokine profile may affect the
overall impact of adipocity on survival. Adiponectin is an
adipocytokine having protective functions against athero-
sclerosis27–30 and insulin resistance.31 In the previous
reports,27 adiponectin plasma level is lower in subjects with
higher BMI. Zoccali et al.32 showed that hemodialysis
patients have two to three times higher plasma adiponectin
levels than the healthy controls, but that an increased
adiponectin was the predictor of a lower risk for CVD events
in hemodialysis patients. We recently showed that adiponec-
tin in uremic plasma was apparently intact upon gel filtration
and immunoblotting,33 and the inverse relationship between
body fat and plasma adiponectin level was no longer
significant in hemodialysis patients.34 In addition, the
adiponectin/leptin ratio was significantly higher in the
hemodialysis patients than that in the healthy control
subjects,34 suggesting the alteration in plasma adipocytokine
profile in the dialysis patients.
The association between an increased LMI and reduced
CVD death risk was not significant in univariate analyses, but
it was significant only after adjustment for other confounding
factors. We interpret these data to indicate that an increased
muscle mass has a significant, but only minor influence on
reduced risk for CVD death. An increased muscle mass is
associated with physical activity and exercise training.35
Exercise can improve arterial stiffness in hemodialysis
patients.36 Arterial stiffness is an independent predictor of
CVD death in hemodialysis patients, as shown by us37 and
others.38 In addition, although a recent study36 failed to
detect such a beneficial metabolic effect of exercise in a small
number of hemodialysis patients, exercise may improve
insulin resistance in uremia, another independent predictor
of CVD mortality in hemodialysis patients.8 Thus, the
observed link between LMI and CVD death in hemodialysis
patients may indicate the importance of physical activity and
its metabolic effect in CVD.
Kaizu et al.39 reported that Japanese hemodialysis patients
showed a U-shaped association between BMI and mortality,
and that those with BMI419.0 kg/m2 and those with
BMIo16.9 kg/m2 had a higher risk of mortality than those
with a BMI of 17.0–18.9 kg/m2. In contrast, we did not find
the U-shaped association, but the inverse association between
BMI and mortality in the 808 Japanese dialysis patients.
Another study by Iseki et al.40 showed an inverse association
between BMI and mortality in 1167 Japanese hemodialysis
patients. Furthermore, the Japanese Society for Dialysis
Therapy41 reported that mortality risk in 1 year showed an
inverse association with BMI in 54 287 Japanese hemodialysis
patients. Thus, the U-shaped association between BMI and
mortality risk, reported by Kaizu et al., was not confirmed by
these larger epidemiological studies in Japan. Although it is
unknown what makes the results by Kaizu et al. different
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from other studies, the subject number, selection of the
subjects, and follow-up period may have affected the results.
Kaizu et al. enrolled 116 non-diabetic dialysis patients who
already had survived the initial 2 years of hemodialysis at
entry, and the follow-up period was 12 years. The other
studies had a much larger number of subjects, and did not
exclude those with diabetes mellitus or those having dialysis
duration shorter than 2 years, but the follow-up periods were
shorter than that of Kaizu et al.
Wong et al.42 and Johansen et al.43 reported that Asians on
hemodialysis in the US do not have better survival at higher
BMI, and the U-shaped association was reported for Asian
dialysis patients in the US.42 These results are in contrast to
most of other studies from the US and European countries
showing the survival advantage in obese or overweight
dialysis patients,12,44–47 although a study from France16 did
not find such a significant association. Although we cannot
readily answer the reasons for the different epidemiology for
Asians in the US, the difference in baseline BMI may affect
the results. Asian dialysis patients including the Japanese are
leaner than the other ethnic groups. Another explanation
would be the difference in genetic background, lifestyle, and
interaction of these factors. Asians tend to more easily
develop diabetes mellitus when exposed to Western lifestyle
at a lower BMI than the white,48 and it may cancel out the
survival advantage in high-BMI categories. Taken together,
most of these studies agree that a low BMI predicts poor
survival of hemodialysis patients regardless of the different
ethnic groups, and that most of the dialysis patients have a
lower risk in high-BMI categories. However, the survival
advantage in high-BMI categories may be cancelled out in the
long run in a subgroup of patients who are more susceptible
to obesity-related health problems.
We found that FMI and LMI are differently correlated
with other markers of nutrition, such as total cholesterol and
serum albumin. Serum albumin and creatinine levels were
correlated positively with LMI. Total cholesterol correlated
positively with FMI, and negatively with LMI. These results
indicate that fat mass and lean mass reflect the different
aspects of protein-energy malnutrition in hemodialysis patie-
nts. Lean mass, serum albumin, and serum creatinine appear
to form one group of markers for ‘protein malnutrition’,
whereas fat mass and total cholesterol are in another group of
markers for ‘energy malnutrition’ in the hemodialysis
population.
Malnutrition in the dialysis population often coexists with
inflammation.9,11 However, in the present study, CRP was
not significantly associated with FMI or LMI at baseline.
Presumably, these indices of body composition can serve as
the markers of nutritional status during a much longer term
than the serum CRP, a marker of acute inflammation.
In the present study, we showed negative correlations of
hemodialysis duration with BMI and LMI, but not with FMI,
suggesting that hemodialysis patients tend to lose their lean
mass during long duration of dialysis. Similarly, aging is
known to affect body composition. Lean mass decreases but
fat mass increases during aging in the general population.49
Interestingly, in our previous studies,50,51 fat mass increased
during the initial 3 years of hemodialysis treatment, but
decreased thereafter. These studies indicate the difference in
malnutrition found in aged people and long-term hemodia-
lysis patients.
There are several limitations in the present study. First, we
did not collect data of non-fatal events, but only fatal events.
Therefore, we were unable to separately analyze the risk
factors of event occurrence and risk factors of fatality
following the event.52 Second, because the number of deaths
was relatively small, statistical power might not have been
strong enough to detect the predictive ability of some risk
factors such as serum albumin, CRP, and cholesterol in
multivariate analyses. Also, we were unable to reliably
perform subanalyses in men and women, or in diabetic and
non-diabetic patients, because of the cohort size. Third,
because we did not include data on history of previous CVD
and medications, we cannot rule out the confounding effects
of these factors. Fourth, because the hemodialysis patients in
this cohort were selected on the basis of availability of DEXA
scans, there may be a selection bias. Severely ill patients were
possibly excluded, although DEXA scans were performed as
one of the routine tests for renal bone disease. Fifth, the
measurement of lean mass by DEXA may have overestimated
the actual fat-free mass in some subjects. Excess body fluid
would have increased the DEXA-measured ‘lean mass’.
Although we tried to avoid such influence of fluid excess
on lean mass by using ‘dry weight’ minus fat mass, the lean
mass determined as such may still be inaccurate in patients
with polycystic kidney disease. Finally, the present findings in
the Japanese patients need to be confirmed in dialysis
patients of other ethnicities.
In conclusion, we showed that both body fat mass and
lean mass were independent predictors of outcomes in the
cohort of hemodialysis patients. Further studies are needed to
clarify whether interventions to increase body fat and lean
mass can reduce the risk of death in hemodialysis patients.
MATERIALS AND METHODS
Study design and subjects
This is an observational study in a retrospective cohort consisting of
808 patients on maintenance hemodialysis in Inoue Hospital, Suita,
Japan. The patients were selected from the entire patients of the
dialysis center on the basis of availability of data of whole-body
DEXA during the period between 1993 and 2000. The baseline data
including serum biochemistry were collected in the same month
when DEXA scans were performed. The clinical diagnoses of the
primary renal disease were chronic glomerulonephritis (N¼ 459),
diabetic nephropathy (N¼ 161), polycystic disease (N¼ 45),
hypertensive nephrosclerosis (N¼ 27), toxemia of pregnancy
(N¼ 15), gout (N¼ 13), lupus nephritis (N¼ 8), and others/
unknown (N¼ 80). The patients were dialyzed for 9–12 h per week
using bicarbonate dialysate. Kt/V (1.4170.31, mean7s.d.) was
available for 692 out of the 808 dialysis patients. The other baseline
characteristics of the subjects are given in Table 1. The subjects were
followed for a mean period of 54728 months, and the relationship
554 Kidney International (2006) 70, 549–556
o r i g i n a l a r t i c l e R Kakiya et al.: Body composition and survival of dialysis patients
between the baseline data and outcomes was statistically analyzed.
This study was approved by the ethical committee of the hospital.
Measurement of body composition by DEXA
Body weight in this study refers to ‘dry weight’. Body fat mass was
measured by DEXA using a QDR-2000 (Hologic, Waltham, MA,
USA) with the pre-installed software as described previously.53 Fat-
free mass (lean mass) was calculated by subtracting fat mass from
‘dry weight’ to avoid the possible influence of body fluid excess on
lean mass measured by DEXA. Previous studies54 reported that
following one session of hemodialysis fat mass by DEXA did not
change, whereas DEXA-measured lean mass excluding bone showed
a significant decrease, as predicted by the body weight reduction by
water removal. Body weight, fat mass, and lean mass (kg) were
standardized by squared height (m2), and expressed in kg/m2 as
BMI, FMI, and LMI, respectively.53
Biochemical assays and other measurements
Blood samples were taken just before starting a dialysis session.
Hematocrit, serum albumin, total cholesterol, and CRP levels were
measured by routine laboratory methods. BP was measured at
supine position before dialysis sessions, and the average of 12
measurements of the month was used for analysis.
Statistical methods
Data were summarized as mean7s.d. Difference in means between
groups was evaluated by analysis of variance. As CRP did not have
normal distribution it was summarized as median (range), and
comparison among groups was made by Kruskal–Wallis test.
Categorical data were presented as percentages and compared
among groups by w2 test. Correlation was evaluated by simple linear
regression analysis. BMI, FMI, and LMI were divided into tertiles,
and survival curves were estimated by the Kaplan–Meier method and
evaluated by log-rank test. Univariate and multivariate Cox
proportional hazards models were used to calculate hazards ratios
for possible predictors of outcomes. P-values ofo0.05 were taken as
statistically significant. All these calculations were performed by a
Windows personal computer with statistics software StatView 5
(SAS Institute Inc., Cary, NC, USA).
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